rs266729 — ADIPOQ -11391G>C

Promoter variant reducing adiponectin transcription, increasing T2D, NAFLD, and cardiovascular disease risk

See your personal result for ADIPOQ

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Adiponectin Promoter Switch — When Your Gene Runs Quiet

Adiponectin is the most abundant adipokine the body produces, secreted almost exclusively by fat tissue and acting as a master regulator of insulin sensitivity11 master regulator of insulin sensitivity
a hormone that activates AMPK in muscle and liver, suppresses hepatic glucose output, and reduces inflammation throughout the vascular system. The ADIPOQ gene's promoter region — the molecular switch that determines how actively the gene is transcribed — contains several functional variants that alter circulating adiponectin levels. The rs266729 variant sits approximately 11,391 base pairs upstream of the ADIPOQ transcription start site, where a C-to-G substitution at this position demonstrably dampens gene expression and lowers adiponectin output in carriers.

This SNP is catalogued at dbSNP as a 2 KB upstream regulatory variant at chromosome 3 position 186,841,685 (GRCh38). The G allele has been consistently identified across independent meta-analyses as a low-penetrant but replicable risk factor for type 2 diabetes, non-alcoholic fatty liver disease, and cardiovascular disease — driven primarily by reduced adiponectin transcription that impairs the body's natural insulin-sensitizing and anti-inflammatory signalling.

The Mechanism

The rs266729 C>G substitution alters a transcription factor binding site22 transcription factor binding site
proteins that attach to specific DNA sequences and drive or repress gene expression in the ADIPOQ proximal promoter. Electrophoretic mobility shift assays have demonstrated that the G allele reduces the binding affinity of activating transcription factors at this site, lowering ADIPOQ transcriptional activity relative to the C allele. The downstream consequence is reduced circulating adiponectin — particularly the high-molecular-weight (HMW) multimeric form that drives insulin sensitisation and vascular protection.

Adiponectin signals through two receptors: AdipoR133 AdipoR1
predominantly in skeletal muscle; activates AMPK to increase fatty acid oxidation and glucose uptake and AdipoR244 AdipoR2
predominantly in liver; activates PPARα to reduce lipid accumulation and hepatic inflammation. When adiponectin levels are chronically low because the promoter runs quiet, both pathways are under-activated: insulin sensitivity falls, hepatic fat accumulates, vascular inflammation rises, and the risk of metabolic disease increases across multiple organ systems.

The Evidence

The landmark meta-analysis by Sun et al.55 Sun et al.
7 studies, 12,323 total subjects established that the G allele increases T2D risk with a generalized odds ratio of 1.13 (95% CI 1.02–1.25) and an additive model OR of 1.13 per G allele (95% CI 1.06–1.19). An earlier meta-analysis by Gong et al.66 Gong et al.
10,267 T2D cases and 12,837 controls across multiple ethnicities found a very similar estimate: G allele OR 1.08 (95% CI 1.01–1.15, P=0.034), classifying rs266729 as "a low-penetrant risk factor for developing T2D."

Cardiovascular risk is compounded. A comprehensive meta-analysis by Kanu et al.77 Kanu et al.
65 studies, 19,106 CVD cases and 31,629 controls found significant increases in cardiovascular disease risk for rs266729 in both the dominant and heterozygote genetic models. Trial sequential analysis confirmed sufficient evidence "to reach concrete conclusions."

Non-alcoholic fatty liver disease (NAFLD) shows particularly strong genotype-dose effects. Zheng et al.88 Zheng et al.
systematic review and meta-analysis, 2,619 NAFLD cases and 1,962 controls across 10 studies found that the G allele nearly doubled NAFLD risk in the allelic model (OR 1.72, 95% CI 1.34–2.21) and that GG homozygotes faced a 2.69-fold risk increase (95% CI 1.84–3.92). Associations were consistent across Asian and Caucasian populations.

At the tissue level, Divella et al.99 Divella et al. demonstrated in colorectal cancer patients that CG and GG carriers have significantly lower circulating adiponectin than CC homozygotes (P=0.034), confirming the functional consequence of the transcriptional impairment. G allele carriers also showed elevated TNF-α, connecting reduced adiponectin to heightened inflammatory signalling.

Practical Actions

The rs266729 G allele's primary effect is reduced adiponectin output, which means interventions that naturally boost adiponectin expression are particularly relevant. Omega-3 fatty acids (EPA and DHA) activate PPARγ in adipocytes1010 activate PPARγ in adipocytes
the master transcriptional regulator of adipogenesis and adiponectin secretion, stimulating ADIPOQ transcription and partially compensating for reduced promoter activity. In randomised trials, 3–4 g/day EPA/DHA supplementation raises adiponectin by 10–25% in insulin-resistant individuals.

Dietary fat composition also modulates ADIPOQ expression through PPARγ. Monounsaturated fatty acids (olive oil, avocados, almonds) and polyunsaturated fats preferentially activate PPARγ, while saturated fat suppresses it. For G allele carriers whose promoter is already operating at reduced capacity, minimising saturated fat and replacing it with MUFA or PUFA has the most evidence for raising adiponectin toward protective levels.

Monitoring adiponectin levels directly is meaningful for this genotype — particularly if other metabolic risk factors are present. Low adiponectin (<5 µg/mL in men, <8 µg/mL in women) substantially amplifies the risk of the associated conditions, and tracking changes in response to dietary intervention gives direct feedback on whether the compensation is working.

Interactions

rs266729 is in moderate-to-high linkage disequilibrium with rs17300539 (-11391G>A), the other functional ADIPOQ promoter SNP already on the platform, as well as with rs2241766 (+45T>G, Gly15Gly in exon 2) and rs1501299 (+276G>T, intron 2). Haplotype combinations across these four variants produce stronger effects on adiponectin levels than any single SNP alone — the A-C haplotype combining rs17300539-A and rs266729-C is associated with greater adiponectin elevation and better lipid outcomes after bariatric surgery than either allele alone.

Emerging data suggest interaction with TCF7L2 variants (particularly rs7903146): TCF7L2 regulates adipocyte differentiation and function, and the combination of TCF7L2 T-allele risk with reduced adiponectin from rs266729 G-allele may identify individuals with the highest dietary fat sensitivity. This interaction candidate is described for supervisor review.

Nutrient Interactions

omega-3 fatty acids altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

CC Normal Adiponectin Promoter Normal

Standard adiponectin production, no genotype-driven metabolic risk

You carry two copies of the C allele at rs266729, the common protective genotype. About 52% of people of European descent share this genotype. Your ADIPOQ promoter functions at full activity, supporting normal adiponectin secretion. This genotype is not associated with increased T2D, NAFLD, or cardiovascular risk through this particular variant. Population meta-analyses using CC as the reference confirm that G-allele carriers bear excess risk relative to you.

CG Reduced Adiponectin Promoter Intermediate

One copy of the risk allele — modestly elevated T2D, NAFLD, and CVD risk

The G allele at rs266729 reduces transcription factor binding at the ADIPOQ promoter, lowering adiponectin output. Because inheritance is additive, one G allele gives you roughly half the adiponectin-lowering effect of GG. Adiponectin levels will not be dramatically reduced, but the directional effect is established across multiple populations. In the presence of overweight, insulin resistance, or dyslipidaemia, the reduction in adiponectin signalling has more practical consequences than it would in a lean, metabolically healthy individual.

Studies consistently show CG carriers have lower circulating adiponectin than CC carriers, elevated inflammatory markers (TNF-α), and greater risk of NAFLD across Asian and Caucasian cohorts.

GG Low Adiponectin Promoter Reduced

Two copies of the risk allele — significantly reduced adiponectin, elevated T2D, NAFLD, and CVD risk

The additive dose-response is clear across multiple meta-analyses: each G allele raises T2D risk by approximately 13%, so two G alleles roughly double the per-allele effect. The mechanism runs through reduced ADIPOQ transcription, lower HMW adiponectin, blunted AMPK activation in muscle and liver, impaired PPARα signalling in hepatocytes (promoting NAFLD), and reduced vascular anti-inflammatory protection.

In the Iranian case-control study by Alimi et al. (2021), the GG genotype showed OR 2.43 for T2D even after controlling for age and sex. In the NAFLD meta-analysis by Zheng et al. (2022), the GG homozygote recessive model showed OR 2.35, and the homozygous model OR 2.69 — robust estimates that held across Asian and Caucasian populations.

Because adiponectin has simultaneous effects on insulin signalling, hepatic fat metabolism, and vascular inflammation, GG carriers face coordinated elevation in risk across conditions that share insulin resistance as a root cause: type 2 diabetes, NAFLD/NASH, metabolic syndrome, and atherosclerotic cardiovascular disease.